Published Erratum
doi: 10.1016/S2213-8587(17)30369-8.
Correction to Lancet Diabetes Endocrinol 2016; 4: 1004-16
- PMID: 29173506
- DOI: 10.1016/S2213-8587(17)30369-8
Item in Clipboard
Published Erratum
Correction to Lancet Diabetes Endocrinol 2016; 4: 1004-16
Lancet Diabetes Endocrinol.
2017 Dec.
No abstract available
Erratum for
-
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.Lancet Diabetes Endocrinol. 2016 Dec;4(12):1004-1016. doi: 10.1016/S2213-8587(16)30267-4. Epub 2016 Sep 16. Lancet Diabetes Endocrinol. 2016. PMID: 27651331 Clinical Trial.
Similar articles
-
Correction to Lancet Diabetes Endocrinol 2018; 6: 186-96.Lancet Diabetes Endocrinol. 2018 Apr;6(4):e4. doi: 10.1016/S2213-8587(18)30082-2. Epub 2018 Mar 6. Lancet Diabetes Endocrinol. 2018. PMID: 29523429 No abstract available.
-
Correction to Lancet Diabetes Endocrinol 2016; 4: 233-43.Lancet Diabetes Endocrinol. 2018 Mar;6(3):e3. doi: 10.1016/S2213-8587(18)30053-6. Lancet Diabetes Endocrinol. 2018. PMID: 29475499 No abstract available.
-
Correction to Lancet Diabetes Endocrinol 2018; 6: 17-26.Lancet Diabetes Endocrinol. 2018 Jan;6(1):e1. doi: 10.1016/S2213-8587(17)30410-2. Lancet Diabetes Endocrinol. 2018. PMID: 29273167 No abstract available.
-
Correction to Lancet Diabetes Endocrinol 2017; 5: 864-76.Lancet Diabetes Endocrinol. 2017 Dec;5(12):e8. doi: 10.1016/S2213-8587(17)30375-3. Lancet Diabetes Endocrinol. 2017. PMID: 29173505 No abstract available.
-
Correction to Lancet Diabetes Endocrinol 2016; 4: 963-64.Lancet Diabetes Endocrinol. 2017 Dec;5(12):e8. doi: 10.1016/S2213-8587(17)30370-4. Lancet Diabetes Endocrinol. 2017. PMID: 29173504 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
